WAKEFIELD, Mass.–Implant Sciences Corporation (NYSE Alternext US: IMX), a high technology supplier of sophisticated systems and sensors for the homeland security market and related industries, today announced that its Board of Directors has retained Noblemen Holdings, LLC (“Noblemen”) to provide M&A and management advisory services to assist in creating, evaluating, and implementing strategic alternatives for the Company. Phillip C. Thomas, President and CEO of Implant Sciences, stated, “Through the efforts of the Noblemen Group, we have received inquiries from a number of sources who have expressed an interest in a potential transaction with the Company. As such, we are moving to be in a position to evaluate various alternatives on behalf of our shareholders, each intended to maximize our corporate value. This process is underway and we are endeavoring to move it along as expeditiously as possible. In parallel with these efforts, we continue to execute on our operating plan to the best of our ability during a financing/business environment which is challenging and unpredictable. In the last year, we believe we have made significant progress in the disposition of non-strategic assets and focusing our efforts on the expansion of our security products business and we continue our efforts in these areas.” There can be no assurance that the evaluation of strategic alternatives will result in any agreements or transactions. The Company does not intend to disclose developments with respect to the evaluation of strategic alternatives unless and until its Board of Directors deems it appropriate. About Implant Sciences Implant Sciences develops, manufactures and sells sophisticated sensors and systems for the Security, Safety and Defense (SS&D) industries. The Company has developed proprietary technologies used in its commercial portable and bench-top explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.